Global Equity Markets Overview
Over the past several weeks we have outlined the case for our increasingly bullish outlook, noting that market internals remain favorable and...
121 Views
Global Strategy: Opportunities in Health Care & Materials Stocks
Price and relative strength trends continue to improve for our international equal-weight Health Care Sector.We recommend adding exposure, and...
241 Views
Astellas Mid-Term Plan FY18-FY20e: Concerns Remain Over Growth Post-Xtandi LOE
Astellas Pharma Inc (4503 JP) announced it FY18-20e mid-term plan on May 22, 2018 While our FY20e sales estimates are in-line with the company...
162 Views
Astellas FY17 Results and FY18e Guidance – No Major Surprise
Astellas Pharma Inc (4503 JP) FY17 results Xtandi (up 17% to ¥295b) and mirabegron (up 28% to ¥126b) ramp-up compensate for lackluster domestic...
116 Views
Japan Pharma - FY17e Earnings Preview (I)
Astellas Pharma Inc (4503 JP) - April 26, 2018FY18e potential guidance Moderate Xtandi and Tarceva growth and Vesicare US patent expiry led y-o-y...
97 Views